Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Stiegelbauer, V; Perakis, S; Deutsch, A; Ling, H; Gerger, A; Pichler, M.
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
World J Gastroenterol. 2014; 20(33):11727-11735 Doi: 10.3748/wjg.v20.i33.11727 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Pichler Martin
Stiegelbauer Verena
Co-Autor*innen der Med Uni Graz
Deutsch Alexander
Gerger Armin
Hasenleithner Samantha

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Colorectal cancer (CRC) is the third most common cancer in western countries. Despite significant improvement in available treatment options, CRC still remains the second leading cause of cancer-related death. Traditionally, 5-fluorouracil has been used as the main chemotherapy drug for treatment of metastatic CRC (mCRC). However, during the last two decades more effective chemotherapeutic agents such as oxaliplatin, irinotecan and the monoclonal antibodies cetuximab, panitumumab and bevacizumab have been used in clinical practice. More recently, the therapeutic armamentarium has been supplemented by the monoclonal antibodies bevacizumab, cetuximab and panitumumab as well as the protein-trap aflibercept and the small molecule multi-kinase inhibitor regorafenib. One of the major problems for the management of CRC is the inherent or acquired resistance to therapeutic approaches. The discovery of microRNAs (miRNAs), a class of small, endogenous, non-coding, single-stranded RNAs that play a role as post-transcriptional regulators, has added new dimensions to the diagnosis and treatment of cancer. Because miRNAs are important regulators of carcinogenesis, progression, invasion, angiogenesis and metastases in CRC, they might serve as potential predictive and prognostic factors and even as therapeutic targets themselves. Several miRNAs are already known to be dysregulated in CRCs and have been linked to biological processes involved in tumor progression and response to anti-cancer therapies. This review summarizes current therapeutic approaches for treating CRC and highlights the role of miRNAs as novel predictive biomarkers and potential drug targets in CRC patients.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - genetics
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - metabolism
Colorectal Neoplasms - pathology
Gene Expression Regulation, Neoplastic - drug effects
Genetic Testing - methods
Humans -
MicroRNAs - genetics
MicroRNAs - metabolism
MicroRNAs - therapeutic use
Molecular Targeted Therapy -
Patient Selection -
Precision Medicine -
Predictive Value of Tests -
Prognosis -
Signal Transduction - drug effects

Find related publications in this database (Keywords)
Colorectal cancer
Epidermal growth factor receptor
Targeted therapy
© Med Uni Graz Impressum